Watch for the planned Phase 3 trial design and enrollment update in mid-2027; the activist's next move (proxy contest or board negotiation) could surface in coming weeks. The PIPE's $3.75 price is at a ~15% discount to the current $4.41 market price, suggesting near-term overhang.
Drugs in focus
ABEO drug pipeline →ABO-801
● Neutral Named in this press release- Impact
- Phase
- Phase 2 completed / Phase 3-ready
- Time to market
- ABO-801 is Phase 3-ready but no Phase 3 trial has been announced. Assuming a typical 1-2 year Phase 3 program plus FDA review, potential approval would be at least 3-4 years away, though the Fast Track designation could accelerate the timeline.
- Next catalyst
- None dated
What to watchWatch for the initiation of a Phase 3 trial for ABO-801 in eosinophilic esophagitis, which would be the next meaningful drug-specific catalyst. Near term, monitor the activist investor situation (James Russell's 6.1% stake and board-change demands) and the registration statement filing for the PIPE shares, as these could drive further volatility. The Q3 earnings beat and ZEVASKYN revenue growth ($13.5M, up 18% QoQ) provide a commercial foundation, but the dilutive financing and activist pressure create a mixed setup.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 9 $2.54entry
- T+1 · 7d ago −3.35%α −2.98% · $2.46
- T+5 · 17h ago +2.36%α +4.05% · $2.60
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abeona Therapeutics acquires ABO-801 (formerly APT-1011), a Phase 3-ready oral therapy for eosinophilic esophagitis, from Ellodi Pharmaceuticals for $20M in stock with no upfront cash, plus up to $60M in milestones and tiered royalties. Concurrently, the company raises $30M in a PIPE financing at $3.75/share, with participation from leading life sciences investors. The deal diversifies Abeona's pipeline beyond its commercial gene therapy ZEVASKYN, but the PIPE dilutes existing holders by ~25% and the activist stake (6.1% from October 23) adds governance pressure.
Key Financial Metrics
Key Facts
- Acquired ABO-801 (EoE candidate) from Ellodi for $20M in stock, no upfront cash; up to $30M FDA approval milestone, $30M sales milestones, and low-to-mid teen royalties.
- ABO-801 has FDA Orphan Drug and Fast Track designations; two Phase 3 studies completed (neither met co-primary symptom endpoint, but showed histologic/endoscopic activity).
- Planned Phase 3 study initiation mid-2027; topline results expected by end of 2028.
- PIPE financing: $30M gross proceeds from 6.4M shares at $3.75/share and pre-funded warrants for 1.6M shares at $3.7499.
- PIPE investors include Nantahala Capital, Marshall Wace, Monashee, Perceptive Advisors, TPG, and other healthcare funds.
- Activist James Russell disclosed a 6.1% stake on October 23, requesting board changes and management review.
- Proceeds will fund pipeline development and ZEVASKYN commercialization.
Financial Impact
PIPE adds $30M gross proceeds; acquisition consideration $20M in stock; total potential milestones up to $60M plus royalties. Dilution from PIPE: ~25% of pre-deal shares outstanding (6.4M shares + 1.6M pre-funded warrants vs. ~25M pre-deal shares).
Risk Factors
- ABO-801's prior Phase 3 failures on the symptom endpoint increase regulatory risk; the new Phase 3 may not succeed.
- PIPE dilution (~25%) pressures existing holders; activist may push for further changes or a sale.
- Commercial execution of ZEVASKYN remains unproven; cash burn may accelerate without near-term revenue.
- Ellodi's milestone/royalty obligations add future cost if ABO-801 succeeds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398196 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Viewing Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers